Olmesartán/Amlodipino/Hidroclorotiazida Cinfamed (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine, hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Cinfamed, are antihypertensive agents presented as a tablet for oral use. They treat high blood pressure in adult patients and are used when single‑component therapy does not achieve target control.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Cinfamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine/Hydrochlorothiazide is a combination antihypertensive used to manage elevated blood pressure across several clinical scenarios. - Essential hypertension: lowers systolic and diastolic pressure in adults. - Resistant hypertension: provides additional control when other agents are insufficient. - Hypertension with peripheral edema: amlodipine component helps counteract fluid retention while maintaining blood pressure reduction.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness of the skin. - Fatigue: general tiredness or lack of energy. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Electrolyte imbalance: especially low potassium or sodium levels. - Acute renal impairment: sudden decline in kidney function. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Patients should be evaluated for specific risk factors before initiating therapy. - Blood pressure monitoring: ensure adequate control without excessive drop. - Renal function assessment: check creatinine and eGFR regularly. - Electrolyte surveillance: monitor potassium and sodium levels. - Pregnancy avoidance: not recommended during pregnancy due to fetal risk. - Hepatic impairment caution: dose adjustment may be required. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine/HCTZ can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or ARBs with aliskiren in diabetic patients: increased renal adverse events. - Lithium: heightened lithium toxicity. - NSAIDs: may blunt antihypertensive effect and impair renal function. - Cyclosporine: additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive hypotensive effect. - Other antihypertensives: cumulative blood‑pressure lowering. - Antidiabetic agents: possible need for dose adjustment. - Corticosteroids: may reduce diuretic efficacy. - Alcohol: can enhance hypotensive response.